Mario Scartozzi

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 415 citations · Full text

Surgical Oncology, Hepatology, Medicine +8

PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

Fotios Loupakis, Luca Emanuele Pollina, I. Stasi et al. · Journal of Clinical Oncology · 2009 · 402 citations · Full text

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

Mario Scartozzi, Silvia Chiorrini, Riccardo Giampieri et al. · Annals of Oncology · 2008 · 324 citations

Hypertension, Surgical Oncology, Oncology +10

Epidermal Growth Factor Receptor (EGFR) Status in Primary Colorectal Tumors Does Not Correlate With EGFR Expression in Related Metastatic Sites: Implications for Treatment With EGFR-Targeted Monoclonal Antibodies

Mario Scartozzi, Italo Bearzi, Rossana Berardi et al. · Journal of Clinical Oncology · 2004 · 259 citations · Full text

Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

Daniele Santini, Bruno Vincenzi, Raffaele Addeo et al. · Annals of Oncology · 2012 · 211 citations · Full text

Cetuximab Rechallenge, Gastrointestinal Oncology, Medicine +6